The  ||| S:0 E:4 ||| DT
use  ||| S:4 E:8 ||| NN
of  ||| S:8 E:11 ||| IN
immunoglobulin  ||| S:11 E:26 ||| JJ
therapy  ||| S:26 E:34 ||| NN
for  ||| S:34 E:38 ||| IN
patients  ||| S:38 E:47 ||| NNS
with  ||| S:47 E:52 ||| IN
primary  ||| S:52 E:60 ||| JJ
immune  ||| S:60 E:67 ||| JJ
deficiency ||| S:67 E:77 ||| NN
:  ||| S:77 E:79 ||| :
an  ||| S:79 E:82 ||| DT
evidence-based  ||| S:82 E:97 ||| JJ
practice  ||| S:97 E:106 ||| NN
guideline  ||| S:106 E:116 ||| VBD
The  ||| S:116 E:120 ||| DT
standard  ||| S:120 E:129 ||| JJ
treatment  ||| S:129 E:139 ||| NN
for  ||| S:139 E:143 ||| IN
patients  ||| S:143 E:152 ||| NNS
with  ||| S:152 E:157 ||| IN
primary  ||| S:157 E:165 ||| JJ
antibody  ||| S:165 E:174 ||| NN
deficiency  ||| S:174 E:185 ||| NN
is  ||| S:185 E:188 ||| VBZ
immunoglobulin  ||| S:188 E:203 ||| JJ
( ||| S:203 E:204 ||| -LRB-
IG ||| S:204 E:206 ||| NNP
) ||| S:206 E:207 ||| -RRB-
,  ||| S:207 E:209 ||| ,
but  ||| S:209 E:213 ||| CC
the  ||| S:213 E:217 ||| DT
care  ||| S:217 E:222 ||| NN
of  ||| S:222 E:225 ||| IN
these  ||| S:225 E:231 ||| DT
patients  ||| S:231 E:240 ||| NNS
is  ||| S:240 E:243 ||| VBZ
complex ||| S:243 E:250 ||| JJ
.  ||| S:250 E:252 ||| .
These  ||| S:252 E:258 ||| DT
guidelines ||| S:258 E:268 ||| NNS
,  ||| S:268 E:270 ||| ,
initiated  ||| S:270 E:280 ||| VBN
by  ||| S:280 E:283 ||| IN
the  ||| S:283 E:287 ||| DT
Canadian  ||| S:287 E:296 ||| JJ
Blood  ||| S:296 E:302 ||| NNP
Services  ||| S:302 E:311 ||| NNPS
and  ||| S:311 E:315 ||| CC
the  ||| S:315 E:319 ||| DT
National  ||| S:319 E:328 ||| NNP
Advisory  ||| S:328 E:337 ||| NNP
Committee  ||| S:337 E:347 ||| NNP
on  ||| S:347 E:350 ||| IN
Blood  ||| S:350 E:356 ||| NNP
and  ||| S:356 E:360 ||| CC
Blood  ||| S:360 E:366 ||| NNP
Products ||| S:366 E:374 ||| NNPS
,  ||| S:374 E:376 ||| ,
have  ||| S:376 E:381 ||| VBP
been  ||| S:381 E:386 ||| VBN
developed  ||| S:386 E:396 ||| VBN
to  ||| S:396 E:399 ||| TO
facilitate  ||| S:399 E:410 ||| VB
and  ||| S:410 E:414 ||| CC
standardize  ||| S:414 E:426 ||| VB
the  ||| S:426 E:430 ||| DT
care  ||| S:430 E:435 ||| NN
of  ||| S:435 E:438 ||| IN
these  ||| S:438 E:444 ||| DT
patients  ||| S:444 E:453 ||| NNS
by  ||| S:453 E:456 ||| IN
the  ||| S:456 E:460 ||| DT
various  ||| S:460 E:468 ||| JJ
physician  ||| S:468 E:478 ||| NN
specialties  ||| S:478 E:490 ||| NNS
that  ||| S:490 E:495 ||| WDT
are  ||| S:495 E:499 ||| VBP
responsible  ||| S:499 E:511 ||| JJ
for  ||| S:511 E:515 ||| IN
their  ||| S:515 E:521 ||| PRP$
care ||| S:521 E:525 ||| NN
.  ||| S:525 E:527 ||| .
A  ||| S:527 E:529 ||| DT
panel  ||| S:529 E:535 ||| NN
of  ||| S:535 E:538 ||| IN
national  ||| S:538 E:547 ||| JJ
expert  ||| S:547 E:554 ||| NN
immunologists  ||| S:554 E:568 ||| NNS
and  ||| S:568 E:572 ||| CC
methodologists  ||| S:572 E:587 ||| VB
developed  ||| S:587 E:597 ||| VBN
salient  ||| S:597 E:605 ||| JJ
clinical  ||| S:605 E:614 ||| JJ
questions ||| S:614 E:623 ||| NNS
;  ||| S:623 E:625 ||| :
and  ||| S:625 E:629 ||| CC
a  ||| S:629 E:631 ||| DT
systematic ||| S:631 E:641 ||| JJ
,  ||| S:641 E:643 ||| ,
expert ||| S:643 E:649 ||| NN
,  ||| S:649 E:651 ||| ,
and  ||| S:651 E:655 ||| CC
bibliography  ||| S:655 E:668 ||| JJ
literature  ||| S:668 E:679 ||| NN
search  ||| S:679 E:686 ||| NN
up  ||| S:686 E:689 ||| RP
to  ||| S:689 E:692 ||| TO
July  ||| S:692 E:697 ||| NNP
2008  ||| S:697 E:702 ||| CD
was  ||| S:702 E:706 ||| VBD
conducted ||| S:706 E:715 ||| VBN
.  ||| S:715 E:717 ||| .
One  ||| S:717 E:721 ||| CD
thousand  ||| S:721 E:730 ||| CD
eighty-seven  ||| S:730 E:743 ||| JJ
citations  ||| S:743 E:753 ||| NNS
were  ||| S:753 E:758 ||| VBD
retrieved ||| S:758 E:767 ||| VBN
,  ||| S:767 E:769 ||| ,
and  ||| S:769 E:773 ||| CC
102  ||| S:773 E:777 ||| CD
reports  ||| S:777 E:785 ||| NNS
were  ||| S:785 E:790 ||| VBD
used  ||| S:790 E:795 ||| VBN
in  ||| S:795 E:798 ||| IN
the  ||| S:798 E:802 ||| DT
preparation  ||| S:802 E:814 ||| NN
of  ||| S:814 E:817 ||| IN
this  ||| S:817 E:822 ||| DT
guideline ||| S:822 E:831 ||| NN
.  ||| S:831 E:833 ||| .
The  ||| S:833 E:837 ||| DT
recommendations  ||| S:837 E:853 ||| NNS
provide  ||| S:853 E:861 ||| VBP
guidance  ||| S:861 E:870 ||| NN
( ||| S:870 E:871 ||| -LRB-
1 ||| S:871 E:872 ||| LS
)  ||| S:872 E:874 ||| -RRB-
on  ||| S:874 E:877 ||| IN
the  ||| S:877 E:881 ||| DT
complexity  ||| S:881 E:892 ||| NN
of  ||| S:892 E:895 ||| IN
the  ||| S:895 E:899 ||| DT
treatment  ||| S:899 E:909 ||| NN
of  ||| S:909 E:912 ||| IN
these  ||| S:912 E:918 ||| DT
patients ||| S:918 E:926 ||| NNS
;  ||| S:926 E:928 ||| :
( ||| S:928 E:929 ||| -LRB-
2 ||| S:929 E:930 ||| LS
)  ||| S:930 E:932 ||| -RRB-
the  ||| S:932 E:936 ||| DT
established  ||| S:936 E:948 ||| JJ
benefits  ||| S:948 E:957 ||| NNS
of  ||| S:957 E:960 ||| IN
IG  ||| S:960 E:963 ||| NNP
on  ||| S:963 E:966 ||| IN
morbidity  ||| S:966 E:976 ||| NN
and  ||| S:976 E:980 ||| CC
mortality ||| S:980 E:989 ||| NN
;  ||| S:989 E:991 ||| :
( ||| S:991 E:992 ||| -LRB-
3 ||| S:992 E:993 ||| LS
)  ||| S:993 E:995 ||| -RRB-
dosage ||| S:995 E:1001 ||| NN
,  ||| S:1001 E:1003 ||| ,
routes  ||| S:1003 E:1010 ||| NNS
of  ||| S:1010 E:1013 ||| IN
administration ||| S:1013 E:1027 ||| NN
,  ||| S:1027 E:1029 ||| ,
and  ||| S:1029 E:1033 ||| CC
management  ||| S:1033 E:1044 ||| NN
of  ||| S:1044 E:1047 ||| IN
reactions ||| S:1047 E:1056 ||| NNS
;  ||| S:1056 E:1058 ||| :
( ||| S:1058 E:1059 ||| -LRB-
4 ||| S:1059 E:1060 ||| LS
)  ||| S:1060 E:1062 ||| -RRB-
the  ||| S:1062 E:1066 ||| DT
various  ||| S:1066 E:1074 ||| JJ
IG  ||| S:1074 E:1077 ||| NNP
formulations  ||| S:1077 E:1090 ||| VBD
available ||| S:1090 E:1099 ||| JJ
;  ||| S:1099 E:1101 ||| :
( ||| S:1101 E:1102 ||| -LRB-
5 ||| S:1102 E:1103 ||| LS
)  ||| S:1103 E:1105 ||| -RRB-
vaccination  ||| S:1105 E:1117 ||| NN
of  ||| S:1117 E:1120 ||| IN
these  ||| S:1120 E:1126 ||| DT
patients ||| S:1126 E:1134 ||| NNS
;  ||| S:1134 E:1136 ||| :
and  ||| S:1136 E:1140 ||| CC
( ||| S:1140 E:1141 ||| -LRB-
6 ||| S:1141 E:1142 ||| CD
)  ||| S:1142 E:1144 ||| -RRB-
research  ||| S:1144 E:1153 ||| NN
priorities ||| S:1153 E:1163 ||| NNS
.  ||| S:1163 E:1165 ||| .
